Malaysia at a glance
- Population
- 36.0 million 2025
- Life expectancy at birth
- 76.8 years, 2024
- People aged 65 and over
- 8.0 % of people, 2025
- Health spending per person
- 450 US$ per person, 2023
- Doctors
- 2.34 per 1,000 people, 2023
Updated
Reviewed by Chandani Patel
Malaysia Malaria Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Region, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$3.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $0.4 Mn | — | — |
| 2025 (base) | $0.5 Mn | +$0.1 Mn | — |
| 2026 (forecast) | $0.6 Mn | +$0.1 Mn | +25% |
| 2027 (forecast) | $0.7 Mn | +$0.1 Mn | +56.3% |
| 2028 (forecast) | $0.9 Mn | +$0.2 Mn | +95.3% |
| 2029 (forecast) | $1.1 Mn | +$0.2 Mn | +144.1% |
| 2030 (forecast) | $1.4 Mn | +$0.3 Mn | +205.2% |
| 2031 (forecast) | $1.8 Mn | +$0.4 Mn | +281.5% |
| 2032 (forecast) | $2.2 Mn | +$0.4 Mn | +376.8% |
| 2033 (forecast) | $2.8 Mn | +$0.6 Mn | +496% |
| 2034 (forecast) | $3.5 Mn | +$0.7 Mn | +645.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $0.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 25.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, region and end user (see all) |
| Key players | GSK PLC, Serum Institute of India, Bharat Biotech, Sanaria, BioNTech (see all) |
| Regulator in Malaysia | NPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Malaria vaccines protect young children in high-risk areas against malaria, a leading cause of child deaths in Africa.
Key segments of the malaria Vaccines market include product (RTS,S/AS01, R21/Matrix-M and Candidates) and region (Sub-Saharan Africa, Asia and Latin America).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the malaria Vaccines market.
New vaccines, rapid tests and public-private funding for neglected diseases give the malaria Vaccines market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the malaria Vaccines market.
The malaria Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.[2]
[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
[2] Ministry of Health Malaysia. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for malaria Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.
What doctors and scientists are doing in Malaria Vaccines right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
Malaysia
Malaysia
Malaysia
Malaysia
Malaysia
Malaysia
OTC & Nutraceuticals · Malaysia
Medical Devices · Malaysia
Public Health · Global
Public Health · Global
Public Health · Global
Public Health · Global